A recent study investigates the sex-specific mechanisms underlying lower urinary tract dysfunction (LUTD) in aging, revealing significant insights into the therapeutic potential of senolytic treatment. Researchers explored the effects of a senolytic drug combination, **Dasatinib and Quercetin (D&Q), on aged bladders from male and female Diversity Outbred mice, focusing on the role of cellular senescence and endoplasmic reticulum (ER) stress.**

The findings highlight notable baseline differences in the unfolded protein response (UPR) between sexes, with females exhibiting increased expression of PERK pathway components and males showing more efficient ER-associated degradation (ERAD) and autophagy processes. D&Q treatment selectively enhanced ERAD markers in females and improved uroplakin expression and urothelial thickness, indicating a potential therapeutic avenue for mitigating LUTD in older women. This suggests that the aging bladder’s response to stressors may differ significantly by sex, contributing to the observed disparities in LUTD prevalence.

The implications of this research extend to the development of sex-specific therapeutic strategies in aging-related bladder dysfunction. By elucidating the distinct molecular pathways involved in LUTD, this study underscores the importance of integrating sex as a biological variable in aging research. Such insights could accelerate the identification of targeted interventions, potentially refining drug development timelines and improving clinical outcomes for aging populations, particularly for women who are disproportionately affected by LUTD.

Source: academic.oup.com